Pictet Asset Management
VERA icon

Pictet Asset Management’s Vera Therapeutics VERA Stock Holding History

Pictet Asset Management’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53.6M Buy
1,249,414
+197,831
+19% +$7.37M 0.05% 325
2026
Q1 		$42.3M Sell
1,051,583
-340,838
-24% -$14.7M 0.04% 344
2025
Q4 		$70.5M Sell
1,392,421
-46,700
-3% -$1.66M 0.07% 271
2025
Q3 		$41.8M Buy
1,439,121
+666,307
+86% +$15.4M 0.04% 357
2025
Q2 		$18.2M Sell
772,814
-67,444
-8% -$1.52M 0.02% 532
2025
Q1 		$20.2M Sell
840,258
-1,055
-0.1% -$33.9K 0.02% 497
2024
Q4 		$35.6M Buy
841,313
+269,315
+47% +$11.9M 0.04% 367
2024
Q3 		$25.3M Sell
571,998
-51,651
-8% -$1.96M 0.03% 425
2024
Q2 		$22.6M Sell
623,649
-387,901
-38% -$15.4M 0.03% 439
2024
Q1 		$43.6M Sell
1,011,550
-316,990
-24% -$11.3M 0.05% 335
2023
Q4 		$20.4M Buy
1,328,540
+102,393
+8% +$1.3M 0.02% 483
2023
Q3 		$16.8M Buy
+1,226,147
New +$21M 0.02% 501

Other funds holding VERA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Pictet Asset Management's VERA Position: Q2 2026 in Review

Pictet Asset Management increased its Vera Therapeutics (VERA) stake by 19% in Q2 2026, buying an estimated $7.37M and bringing the position to 1,249,414 shares worth $53.6M. The position accounts for 0.05% of the portfolio, ranked #325.

Pictet Asset Management first reported a position in VERA in Q3 2023 and has held it in 12 quarters since. The position peaked at $70.5M in Q4 2025. 219 funds tracked by Wall St. Rank hold VERA as of Q2 2026.

  • Pictet Asset Management held 1,249,414 shares of Vera Therapeutics worth $53.6M as of Q2 2026.
  • Pictet Asset Management bought 197,831 Vera Therapeutics shares in Q2 2026, an estimated $7.37M.
  • Vera Therapeutics made up 0.05% of Pictet Asset Management's portfolio in Q2 2026, its #325 holding.
  • Pictet Asset Management first reported a position in Vera Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • Pictet Asset Management's Vera Therapeutics position peaked at $70.5M in Q4 2025.
  • 219 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.